The Impact of COVID-19 is included in Osteoporosis Drug Market Report. Buy it today to get an advantage.
Request the impact of COVID-19 on your product or industry
Osteoporosis Drug Trends and Forecast
The future of the global osteoporosis drug market looks promising with opportunities in the primary osteoporosis and secondary osteoporosis markets. The global osteoporosis drug market is expected to reach an estimated $17.2 billion by 2030 with a CAGR of 3.2% from 2024 to 2030. The major drivers for this market are rising occurrences of osteoporosis and increase in the elderly population across the globe.
.
A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.
Osteoporosis Drug by Segment
The study includes a forecast for the global osteoporosis drug by drug type, application, and region.
Osteoporosis Drug Market by Drug Type [Shipment Analysis by Value from 2018 to 2030]:
• Parathyroid Hormone Therapy
• Bisphosphonates
• Calcitonin
• Rankl Inhibitors
• Others
Osteoporosis Drug Market by Application [Shipment Analysis by Value from 2018 to 2030]:
• Primary Osteoporosis
• Secondary Osteoporosis
Osteoporosis Drug Market by Region [Shipment Analysis by Value from 2018 to 2030]:
• North America
• Europe
• Asia Pacific
• The Rest of the World
List of Osteoporosis Drug Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies osteoporosis drug companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the osteoporosis drug companies profiled in this report include-
• Pfizer
• Eli Lily
• F. Hoffmann La Roche
• Merck
• Amgen
• Radius Health
• Teva Pharmaceutical Industries
Osteoporosis Drug Market Insights
Lucintel forecasts that RANKL inhibitor will remain the largest segment over the the forecast period due to its increasing adoption to treat osteoporosis in patients with high risk of fractures.
Within this market, primary osteoporosis will remain the larger segment due to surging aging population and growing awareness towards osteoporosis among consumers.
North America will remain the largest region over the forecast period due to existence of major players, rising prevalence of osteoporosis patients, and easy accessibility of branded medications in the region.
Features of the Global Osteoporosis Drug Market
Market Size Estimates: Osteoporosis drug market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.
Segmentation Analysis: Osteoporosis drug market size by drug type, application, and region in terms of value ($B).
Regional Analysis: Osteoporosis drug market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different drug types, applications, and regions for the osteoporosis drug market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the osteoporosis drug market.
Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
FAQ
Q1. What is the osteoporosis drug market size?
Answer: The global osteoporosis drug market is expected to reach an estimated $17.2 billion by 2030.
Q2. What is the growth forecast for osteoporosis drug market?
Answer: The global osteoporosis drug market is expected to grow with a CAGR of 3.2% from 2024 to 2030.
Q3. What are the major drivers influencing the growth of the osteoporosis drug market?
Answer: The major drivers for this market are rising occurrences of osteoporosis and increase in the elderly population across the globe.
Q4. What are the major segments for osteoporosis drug market?
Answer: The future of the osteoporosis drug market looks promising with opportunities in the primary osteoporosis and secondary osteoporosis markets.
Q5. Who are the key osteoporosis drug market companies?
Answer: Some of the key osteoporosis drug companies are as follows:
• Pfizer
• Eli Lily
• F. Hoffmann La Roche
• Merck
• Amgen
• Radius Health
• Teva Pharmaceutical Industries
Q6. Which osteoporosis drug market segment will be the largest in future?
Answer: Lucintel forecasts that RANKL inhibitor will remain the largest segment over the the forecast period due to its increasing adoption to treat osteoporosis in patients with high risk of fractures.
Q7. In osteoporosis drug market, which region is expected to be the largest in next 5 years?
Answer: North America will remain the largest region over the forecast period due to existence of major players, rising prevalence of osteoporosis patients, and easy accessibility of branded medications in the region.
Q.8 Do we receive customization in this report?
Answer: Yes, Lucintel provides 10% customization without any additional cost.
This report answers following 11 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the osteoporosis drug market by drug type (parathyroid hormone therapy, bisphosphonates, calcitonin, RANKL inhibitors, and others), application (primary osteoporosis and secondary osteoporosis), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
For any questions related to Osteoporosis Drug Market, Osteoporosis Drug Market Size, Osteoporosis Drug Market Growth, Osteoporosis Drug Market Analysis, Osteoporosis Drug Market Report, Osteoporosis Drug Market Share, Osteoporosis Drug Market Trends, Osteoporosis Drug Market Forecast, Osteoporosis Drug Companies, write Lucintel analyst at email: helpdesk@lucintel.com. We will be glad to get back to you soon.
Table of Contents
1. Executive Summary
2. Global Osteoporosis Drug Market : Market Dynamics
2.1: Introduction, Background, and Classifications
2.2: Supply Chain
2.3: Industry Drivers and Challenges
3. Market Trends and Forecast Analysis from 2018 to 2030
3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
3.2. Global Osteoporosis Drug Market Trends (2018-2023) and Forecast (2024-2030)
3.3: Global Osteoporosis Drug Market by Drug Type
3.3.1: Parathyroid Hormone Therapy
3.3.2: Bisphosphonates
3.3.3: Calcitonin
3.3.4: RANKL Inhibitors
3.3.5: Others
3.4: Global Osteoporosis Drug Market by Application
3.4.1: Primary Osteoporosis
3.4.2: Secondary Osteoporosis
4. Market Trends and Forecast Analysis by Region from 2018 to 2030
4.1: Global Osteoporosis Drug Market by Region
4.2: North American Osteoporosis Drug Market
4.2.2: North American Osteoporosis Drug Market by Application: Primary Osteoporosis and Secondary Osteoporosis
4.3: European Osteoporosis Drug Market
4.3.1: European Osteoporosis Drug Market by Drug Type: Parathyroid Hormone Therapy, Bisphosphonates, Calcitonin, RANKL Inhibitors, and Others
4.3.2: European Osteoporosis Drug Market by Application: Primary Osteoporosis and Secondary Osteoporosis
4.4: APAC Osteoporosis Drug Market
4.4.1: APAC Osteoporosis Drug Market by Drug Type: Parathyroid Hormone Therapy, Bisphosphonates, Calcitonin, RANKL Inhibitors, and Others
4.4.2: APAC Osteoporosis Drug Market by Application: Primary Osteoporosis and Secondary Osteoporosis
4.5: ROW Osteoporosis Drug Market
4.5.1: ROW Osteoporosis Drug Market by Drug Type: Parathyroid Hormone Therapy, Bisphosphonates, Calcitonin, RANKL Inhibitors, and Others
4.5.2: ROW Osteoporosis Drug Market by Application: Primary Osteoporosis and Secondary Osteoporosis
5. Competitor Analysis
5.1: Product Portfolio Analysis
5.2: Operational Integration
5.3: Porter’s Five Forces Analysis
6. Growth Opportunities and Strategic Analysis
6.1: Growth Opportunity Analysis
6.1.1: Growth Opportunities for the Global Osteoporosis Drug Market by Drug Type
6.1.2: Growth Opportunities for the Global Osteoporosis Drug Market by Application
6.1.3: Growth Opportunities for the Global Osteoporosis Drug Market by Region
6.2: Emerging Trends in the Global Osteoporosis Drug Market
6.3: Strategic Analysis
6.3.1: New Product Development
6.3.2: Capacity Expansion of the Global Osteoporosis Drug Market
6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Osteoporosis Drug Market
6.3.4: Certification and Licensing
7. Company Profiles of Leading Players
7.1: Pfizer
7.2: Eli Lily
7.3: F. Hoffmann La Roche
7.4: Merck
7.5: Amgen
7.6: Radius Health
7.7: Teva Pharmaceutical Industries
.
Buy full report or by chapter as follows
Lucintel has been in the business of market research and management consulting since 2000 and has published over 1000 market intelligence reports in various markets / applications and served over 1,000 clients worldwide. This study is a culmination of four months of full-time effort performed by Lucintel's analyst team. The analysts used the following sources for the creation and completion of this valuable report:
In-depth interviews of the major players in this market
Detailed secondary research from competitors’ financial statements and published data
Extensive searches of published works, market, and database information pertaining to industry news, company press releases, and customer intentions
A compilation of the experiences, judgments, and insights of Lucintel’s professionals, who have analyzed and tracked this market over the years.
Extensive research and interviews are conducted across the supply chain of this market to estimate market share, market size, trends, drivers, challenges, and forecasts. Below is a brief summary of the primary interviews that were conducted by job function for this report.
Thus, Lucintel compiles vast amounts of data from numerous sources, validates the integrity of that data, and performs a comprehensive analysis. Lucintel then organizes the data, its findings, and insights into a concise report designed to support the strategic decision-making process. The figure below is a graphical representation of Lucintel’s research process.
Please sign in below to get report brochure - Osteoporosis Drug Market Report.